Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
Question
Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
Direct answer
Formulary access for oral obesity candidate Foundayo across major PBMs expands commercial volume, supporting Lilly's $27.7 billion H1 GLP-1 revenue base. — bullish pressure on LLY via PBM formulary access driving commercial oral GLP-1 volume adoption.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-18
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs”, revision 1, evidence through 2026-09-18. https://marketontology.com/catalysts/2026-09-18/eli-lilly-h1-glp-1-sales-reach-27-7b-as-oral-obesity-pill-foundayo-secures-pbms-c511b0
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| LLY | ▲Bull | 1–3 months | PBM formulary access driving commercial oral GLP-1 volume adoption | 72 |
Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs
Formulary access for oral obesity candidate Foundayo across major PBMs expands commercial volume, supporting Lilly's $27.7 billion H1 GLP-1 revenue base. — bullish pressure on LLY via PBM formulary access driving commercial oral GLP-1 volume adoption.
GLP-1 sales hit $27.7B in H1 2026 and oral pill Foundayo gained coverage across major PBMs.
- SourceGLP-1 sales hit $27.7B in H1 2026 and oral pill Foundayo gained coverage across major PBMs.
- TransmissionFormulary access for oral obesity candidate Foundayo across major PBMs expands commercial volume, supporting Lilly's $27.7 billion H1 GLP-1 revenue base.
- SummaryEli Lilly generated $27.7 billion in GLP-1 revenue during the first six months of 2026. Its oral obesity medication Foundayo secured broad coverage across major pharmacy benefit managers. New portfolio therapies grew 121% in Q2, providing diversification beyond core injectables.
- LLYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- LLY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- LLY price vs. pre-event level
- LLY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? · news · 2026-09-17
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsLLY VKTX
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Viking raises $575 million to fund obesity pipeline trialsLLY VKTX
- 2026-10-19Viking financing keeps obesity trial runway open through 2028LLY VKTX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.